



Press Release

BioApex, s.r.o. Receives Grant from the Ministry of Industry and Trade of the Czech Republic

Olomouc, Czech Republic (December 15th, 2009) – BioApex, s.r.o., a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat serious cell cycle related disorders including various cancers, today announced that it has received two grants from the Ministry of Industry and Trade of the Czech Republic under the “Operational Programme Enterprise and Innovations (OPEI) 2007-2013,” specifically the „Programme of support INNOVATION – Patent.” The programme is focused particularly on the support for the commercialisation of R&D results and the transfer of technologies onto markets through innovation activities. Among other, the program contributes to the protection of intangible assets such as patents and trademarks. For small and medium-sized enterprises cooperating with universities and public research institutes, grants will cover up to 65% of costs.

Under its collaborative agreement with the Palacký University, Olomouc, Czech Republic and the Warsaw Institute of Organic Chemistry, Warsaw, Poland, BioApex has applied and been granted partial funding for 2 patent applications. BioApex expects to receive substantial refunds under the grants for its patent filing, translation and maintenance costs.

The grants were applied for under Reg. No. 4.1 INP01/124 (Project: Saccharide lupane derivatives, their use and pharmaceutical compositions containing these derivatives), and Reg. No. 4.1 INP01/152 (Project: Substituted 6-(2-aminobenzylamino)purine derivatives as anticancer and antiviral Agents, processes for their preparation and methods of use).

About BioApex, s.r.o.: BioApex owns a proprietary portfolio of small, second and third generation molecule-like compounds derived from plant hormones, emanating from the research of Prof. Miroslav Strnad and his team of scientists at the Laboratory of Growth Regulators in Olomouc, Czech Republic, that inhibit different kinases. Some of the kinases play a central role in the cell cycle, in the regulation of transcription and likely in many proliferative diseases. BioApex’s intellectual property addresses the very broad fields of cell division related disorders and, besides cancers, includes restenosis, rheumatoid arthritis, glomerulonephritis, type I diabetes, multiple sclerosis, Alzheimer’s disease, growth of parasites (animal, protists), graft rejection (host versus graft disease), graft versus host disease, gout and viral disorders. BioApex believes that, to date, there are no commercially available compounds that combine the same mode of action, effectiveness and minimal side effects.

BioApex plans to initially advance a group of promising compounds on which the design, *in vitro* testing and preclinical trials have been completed, to clinical testing.

A second group of compounds will be taken through pharmacokinetic studies and pre-clinical efficacy trials to determine development priorities. BioApex's business model - a tiered strategy with some compounds in an advanced stage of development and encouraging results to date and some compounds in the pipeline for development – is tailored to attract both, industry "partners" and – in addition to governmental grants and loans - private equity to fund operations. With limited resources focused on research and development, BioApex plans to partner with strong pharmaceutical companies that have established sales and marketing channels in BioApex's target areas.

For more information, visit the company's website at www.bioapex.cz